drugset / Trial / NCT05846789
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Phase 2
Recruiting
168 enrolled
Kathy Miller
Breast Cancer Research Foundation · collabGenentech, Inc. · collabSusan G. Komen Breast Cancer Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.
Timeline
- Start
- 2024-07-02
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |